| Id: | acc4886 |
| Group: | 1sens |
| Protein: | ERK1 |
| Gene Symbol: | Mapk3 |
| Protein Id: | Q63844 |
| Protein Name: | MK03_MOUSE |
| PTM: | phosphorylation |
| Site: | Thr202 |
| Site Sequence: | DPEHDHTGFLTEYVATRWYRA |
| Disease Category: | Nervous system diseases |
| Disease: | Head-Twitch Response |
| Disease Subtype: | |
| Disease Cellline: | HEK293T |
| Disease Info: | |
| Drug: | M100907 + gallein |
| Drug Info: | M100907 is a drug in the combination | Gallein is another drug combined with M100907. |
| Effect: | modulate |
| Effect Info: | Drugs can effectively intervene in HTR in the hallucination model by targeting the Gβγ subunit to regulate protein phosphorylation modification in the PLCβ/IP?/Ca??/ERK and cAMP signaling pathways. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 37657742 |
| Sentence Index: | 37657742_10 |
| Sentence: | "Like the 5-HT2A receptor-selective antagonist (R)-[2,3-di(methoxy)phenyl]-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol (M100907), gallein inhibited PLCbeta phosphorylation (pPLCbeta), IP1 production, Ca2+ transients, ERK1/2 phosphorylation (pERK1/2) and cAMP accumulation induced by DOM in human embryonic kidney (HEK) 293T cells stably or transiently transfected with the human 5-HT2A receptor." |
Sequence & Structure:
MAAAAAAPGGGGGEPRGTAGVVPVVPGEVEVVKGQPFDVGPRYTQLQYIGEGAYGMVSSAYDHVRKTRVAIKKISPFEHQTYCQRTLREIQILLRFRHENVIGIRDILRAPTLEAMRDVYIVQDLMETDLYKLLKSQQLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLINTTCDLKICDFGLARIADPEHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINMKARNYLQSLPSKTKVAWAKLFPKSDSKALDLLDRMLTFNPNKRITVEEALAHPYLEQYYDPTDEPVAEEPFTFDMELDDLPKERLKELIFQETARFQPGAPEGP
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 203 | U | Squamous cell carcinoma | Phosphorylation | 19934324 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
